29/11/2025
Dr. Tam and team of Mitosis visited the National Health Products Quality Control Center (NHPQCC) on November 28, 2025 to formally submit the first batch of our vaccines for laboratory testing.
This marks a significant milestone in our registration journey, as these samples will undergo the mandatory quality verification required by the Ministry of Health (MoH) before national approval and distribution.
During the visit, Dr. Tam met with the technical team to review the testing procedures, ensure proper chain-of-custody documentation, and reaffirm Mitosis’ commitment to strict compliance with Cambodia’s regulatory standards. The submitted batch includes products designated for our initial market introduction, and passing this stage is essential for ensuring safety, efficacy, and quality—core pillars of our company mission.
This step reflects our dedication to building a transparent and trustworthy vaccine supply chain in Cambodia. By proactively engaging with the NHPQCC and adhering to WHO-aligned quality assurance processes, Mitosis continues to move forward in bringing high-quality, evidence-based vaccines closer to healthcare providers and the communities who need them most.
Mitosis Bioscience — Life above all. Quality Vaccine. Evidence-Based.
A bio pharmaceutical company dedicated to protecting lives by delivering safe, high-quality, science-based vaccines with improved accessibility.
Find out more about us: https://www.mitosisbioscience.com/home